The global Drug Eluting Stent Market is anticipated to reach USD 9.2 billion by 2024, according to a new report by Grand View Research, Inc. The increasing geriatric population and the high prevalence of artery diseases are the major factors driving the market growth. Sedentary lifestyles, unhealthy dietary habits, and lack of exercise are some of the factors resulting in the increased prevalence of atherosclerosis. As a result, the demand for Drug Eluting Stents (DES) is escalating as atherosclerosis is widely treated using DES. In addition, a constant decline in the price coupled with the reimbursement coverage is spurring the adoption of DES in the treatment of arterial diseases.
Risks, such as thrombosis and disruption of regrowth
of endothelial tissues associated with DES, are challenging the market growth.
In addition, stringent regulatory approval guidelines are impeding the market
growth by restricting the entry of advanced DES, such as bioabsorbable
products, in the developed countries.
Presently, the DES market is highly fragmented with
the presence of many players competing with each other. The key players in the
market are implementing mergers and acquisitions strategies to strengthen their
position in the market by the expansion of market share and customer base.
Browse
Details of Report @
http://www.grandviewresearch.com/industry-analysis/drug-eluting-stent-market
Further key findings from the study suggest:
- The polymer-based coating stent segment was dominating the global
market and is estimated to remain dominant throughout the forecast period.
The increasing adoption of biodegradable stents is mainly driving the
growth of the polymer-based coating stents segment.
- The biodegradable polymer-based drug eluting stents are anticipated
to have a high demand during the forecast period due to aminimally
invasive technique and lesser risk of late stent thrombosis.
- The demand for polymer-free drug eluting stents is going to increase
considerably with new products entering the market, especially in emerging
countries such as Brazil, Mexico, and South Africa.
- China, India, Brazil, and South Africa are anticipated to register a
significant growth in the near future owing to the rising patient
awareness related to DES, presence of the largest pool of geriatric
population prone to arterial diseases, and the surging prevalence of
chronic diseases such as diabetes and cardiac disorders
- Less stringent regulatory approval procedures in Asia Pacific are
offering the easy entry of the new products into the market.
- Some key players operating in the market include Boston Scientific
Corporation, Medtronic, Inc., Abbott Laboratories, Biosensors
International Group, Lepu Medical Technology, Biotronik, Stentys, and
Terumo Medical Corporation.
- North America dominated the global market with a share of 40% in
2015. Technological advancements, such as the introduction of
biodegradable stents primarily, led to the highest revenue generation in
the region.
- In addition, the reimbursement coverage, the presence of a large
target patient population, and a well-defined regulatory framework are a
few factors that are positively affecting the market.
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals, materials,
healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment